Volume 1, Issue 1 *Jan – Mar 2026*

Emerging Trends in Medical Science & Biomedical Advances

ISSN:

etmsba.com

EXPLORING POST-COVID-19 COMPLICATIONS: A MULTISYSTEM BIOMEDICAL PERSPECTIVE

Rashid Akhtar

Assistant Professor Public Health, School of Healthcare and Allied sciences GD Goenka university, Gurugram

ABSTRACT

The global SARS-CoV-2 pandemic has left one of the enduring clinical legacy beyond acute infection: a spectrum of the persistent as well as emergent multisystem complications collectively which is referred to as the post-acute sequelae of the SARS-CoV-2 infection (PASC) or Long COVID. The current paper will unite the current data on epidemiology, pathophysiology, clinical presentation, and potential therapeutic and monitoring meaning of the post-COVID complications in the different body systems. Our model of interactions between immune dysregulation, viral persistence, microvascular injury, autonomic dysfunction, and metabolic reprogramming that lead to chronic pulmonary, cardiovascular, neurological, renal, endocrine, hematological and psychiatric sequelae is based on recent systematic reviews, mechanistic studies and longitudinal cohorts. We present a cross-sectional cohort design of patient recovery, present findings on the sample of consecutive patients representative of report on the prevalence of symptoms and biological indicators, discuss tendencies in order to qualify the original disease severity and vaccination rates and commenting on clinical and public-health implications. This is followed by recommendations on integrated multispecialty clinics, standardised outcome measures, prioritised research question, and policy measures to reduce the burden of long COVID on individuals and health systems, and the paper is concluded.

Keywords: *Long COVID; post-acute sequelae of SARS-CoV-2 infection; multisystem complications; pathophysiology; cohort study; cardiovascular sequelae; neurocognitive impairment.*

INTRODUCTION

1.1 From Acute Infection to a Chronic Health Challenge

It was no secret that in the first months of the COVID-19 pandemic, the global community of clinicians and researchers was focused on the mortality reduction, severe respiratory failure, and the virus control of the distribution. COVID-19 was initially treated as an acute disease and self-limiting of the virus by a majority of individuals who were infected which would be cured in weeks after the virus was removed. However, as the pandemic lasted and the number of people who survived increased, it became increasingly clear that the ways of recovery were highly disproportionate (Wang *et al.*, 2024). A large proportion of individuals still had the ongoing symptoms or new health conditions months or weeks after the conclusion of the acute infection. These long term effects shifted the scientific discussion of short term survival to long term health effects that made COVID-19 not merely an acute infectious disease to long term chronic multisystem disorder to many survivors.

After the post-acute of the COVID-19, it has been associated with a wide spectrum of clinical manifestations of different organ systems. It may also be associated with typical signs of excessive fatigue, exertional dyspnea, chest pain, heart racing, impaired thinking which is also known as brain fog, insomnia, autonomic dysfunction and persistent anosmia or dysgeusia (Munblit *et al.*, 2022). Besides the subjective symptoms, the objective dysfunction of the organ, e.g., incidental cardiovascular disease, the absence of the pulmonary diffusion capacity, kidney malfunction, metabolic imbalance like diabetes, as well as neuropsychiatric pathology, were reported. The existence of such manifestations within the same individual throws light on the systemic nature of post-COVID pathology and justifies why such a pathology is difficult to manage clinically.

1.2 Heterogeneity and Diagnostic Complexity of Post-COVID Conditions

It is regarded as one of the most important properties of the post-COVID complications by the striking heterogeneity of the latter. The symptoms vary as to type and severe condition, duration and organ involvement and define changes with time. Others complain of debilitating and multisystem damage that tightly restricts their daily living and working ability and complains of occasional symptoms such as fatigue or dyspnea. This heterogeneity has been a huge problem to clinicians who are striving to arrive at diagnostic criterion, prognostic variables and standard care protocols (Astin *et al.*, 2023). Long COVID lacks a predictable pattern and cannot be sufficiently explained by a single pathophysiological mechanism in comparison with classical post-infectious syndromes.

Biomarkers commonly used in the diagnosis are also lacking, thus making clinical assessment complicated. As in a considerable percentage of cases, it is available that even though the patients have normal outcomes in normal laboratory analysis and imaging studies, there are high levels of symptoms in the patients who complain. Such differences between subjective and objective outcomes have at some stages occasioned under-reporting or

false perceptions of symptoms particularly in persons who are not hospitalized (Lans *et al.*, 2024). Thus, the urgency to create integrative diagnostic models to interconnect a clinical assessment, functional testing, and new biomarkers is apparent to see the wider perspective of the multidimensional character of the post-COVID illness.



Figure: Heterogeneity and Diagnostic Complexity of Post-COVID Conditions
(Source: Li *et al.*, 2023)

1.3 Epidemiological Burden and Public Health Significance

Post-COVID persistent symptoms have been reported in different study designs due to the differences in the nature of the population under study, definition of the symptoms, and follow-up time. Nevertheless, a systematic review and big population-based research always show the presence of a nontrivial percentage of survivors of COVID-19 with several months or even longer duration of symptoms (van der Feltz-Cornelis *et al.*, 2024). Even though the rates of prevalence can be rather high among the individuals that have been hospitalized or suffered the necessity to get intensive treatment, the prevalence rates of long-term symptoms were also high in community-based cohorts, which contributes to the possibility to assert that the problem of post-COVID complications is not limited to the severe acute disease.

It is important to note that the situation with young adults and patients, who have not had any prior comorbidities, has resulted in perceiving the long-term consequences of COVID-19 as limited to older or more vulnerable populations. Such population reach enhances the extent of societal health impact of post-COVID illnesses because long-term sufferings among the working age population can be turned into low productivity, elevated utilization of health facilities as well as a protracted socioeconomic consequence (Hu *et al.*, 2025). At the systems level, the healthcare infrastructures are now confronted with the need to provide multidisciplinary care to the number of patients who have continued to increase since the onset of the post-COVID era.

1.4 Rationale and Objectives of the Present Study

Despite the fact that the body of literature on post-COVID complications continuously increases at a rapid pace, the gap in the body of knowledge related to the underlying mechanisms, the organ-related patterns, and the best methods of management remains rather large (Wang *et al.*, 2025). The bulk of obtained research is about individual body systems or certain sets of symptoms that are not sufficient to characterize interdependence of post-COVID pathology. Moreover, such is not the case as the study design and outcome measurement also differed, which has hampered the effective cross study comparison and led to evidence based clinical recommendations.

It is on this basis that the present paper aims at providing a multisystem biological method of post-COVID complications. The research will entail the synthesis of current evidence in major organs, summation of findings obtained using the immunology, vascular biology, neurology, and metabolic science, to describe the integrating processes, which appear to be underlying different clinical manifestations of Long COVID (Paterson *et al.*, 2022). In addition, the paper proposes a methodological framework of prospective cohort assessment, which puts emphasis on standardized tests, biomarker combination. By doing so, the study aims at contributing to the better

perception and understanding of post-COVID conditions and is proposed to be also helpful in the future research, clinical practice, and health policy responsiveness to this emerging global health problem.

LITERATURE REVIEW

2.1 Definitions and Nomenclature

Several similar names were also found in the shortlist of the research: post-acute sequelae of SARS-CoV- 2 infection (PASC), Long COVID, and post-COVID syndrome. Different timing thresholds with the persistence criteria among symptoms are dependent on but the majority of large reviews use the post-acute symptoms persisting past 12 weeks of acute infection as the point of demarcation of chronic sequelae (Hendrickson *et al.*, 2025). The setting of similar outcomes measures also remains a priority in order to have a dependable comparison between prevalence and intervention researches.

2.2 Epidemiology and Risk Factors

Studies have given a wide range of estimates of prevalence following different methods in determining cases although systematic summaries of the studies have indicated that prevalence of common persistent complaints involve fatigue, dyspnoea, cognitive impairment and sleep disturbances (Fernández-de-Las-Penas *et al.*, 2023). Organ-specific sequelae, namely, pulmonary fibrosis and cardiovascular problems tend to be higher among hospitalized cohorts, however, community cohorts also represent a problem with high prevalence. Older age, and female sex in the chosen datasets, the high burden of acute symptoms, comorbidities (cardiometabolic disease, obesity), and signal of immune activation in the course of the acute disease are all new risk factors. Vaccination reduces the risk of severe acute disease and in several larger studies appears to cool the risk and severity of certain post-acute cardiovascular and thrombotic outcomes, though the correlation amid vaccination condition and all long Covidia outcomes has yet to be comprehended.

2.3 Pathophysiological Mechanisms

It has been proposed that chronic symptoms are attributed to a multiplicity of biological processes, which are non-mutually exclusive.

Other research documents the viral presence of the RNA or protein in tissues several months after acute infection as the symptom of viral persistence or the state of constant antigenic stimulation that is the evidence of the immune activation of perpetuation. The abnormal or unusual responses of the immune system like the persistence in the infiltration of inflammatory cytokines, anti-self-antibodies, and dysfunctional T cell subsets have been reported in numerous occasions and can continue to occur in multi-organ dysfunction (Bhattacharjee *et al.*, 2023). Neovascular thrombosis and endothelial injury in acute disease could lead to irreversible microcirculatory dysfunction and organ ischemia, which is probably the cause of a proportion of the cardiopulmonary and neo cognitive changes. The dysfunction of autonomic nervous system and small fibre neuropathies have been mentioned as having caused the orthostatic and intolerance, palpitations, and the exertional intolerance. It suggested mitochondrial dysfunction factors and partial mitochondrial metabolic re-arrangement as the causes of the chronic fatigue and exercise-intolerability. The convergent processes provide a chance to possess a biologically pertinent approach to clinical heterogeneity of Long Covids.

2.4 Organ-System Evidence

2.4.1 Pulmonary Sequelae

Pulmonary complications are persistent ground-glass opacities, fibrotic parenchymal alterations on radiographs, restrictive physiology on pulmonary function tests and persistent exertional dyspnoea (Ashmawy *et al.*, 2024). The persistence of the effects of the initial pneumonia and mechanical ventilation exposure are linked to the risk of the persistent pulmonary impairment, but less severe cases show interstitial changes. Longitudinal imaging and functional studies are necessary to the characterization of the evolution of these lesions as well as the percentage progression to permanent fibrosis.

2.4.2 Cardiovascular Complications

The cardiovascular representation of the COVID-19 is seen in the acute stage, and it is becoming more apparent that high risks of myocarditis, arrhythmias, heart failure, thromboembolic events, and hypertension are emerging in the convalescent groups. The meta-analyses conducted as part of cohort studies provide suggestions of relative risks of myocarditis in the first year of having been infected (Parotto *et al.*, 2023). The current longitudinal data show that a subset of the survivors have partially unresolved myocardial inflammation or cardiac functional defects which can be detected with diagnostics and advanced imaging. Vaccination also appears to reduce a cardiovascular system infection since it reduces the acute infection severity.

2.4.3 Neurological and Neuropsychiatric Manifestations

Common symptoms are neurocognitive dysfunction, also known as brain fog, and headaches and a loss of smell and taste (anosmia) and dysgeusia, sleeplessness, anxiety, and depression. The cause of the mechanism is explained by direct neurotropism, micro-vascular damage and silent infarcts, immune-mediated neuronal injury including autoimmunity and long-term systemic inflammation (Negrut *et al.*, 2024). Interest overlap in

biomarkers and studies of particular therapies underlines common interests in the research in the cross-over between post-infectious fatigue-related syndromes such as ME/CFS.

2.4.4 Renal, Endocrine, Haematological and Other Systems

Acute renal failure is a predictor of the renal dysfunction in patients with COVID-19 in the long-term. Endocrine disfunctions include a defect in the metabolism that involves glucose whereby there are documented cases of the development of new diabetes, thrombotic tendency and chronic coagulopathy have also been indicated to generate harm to the microvasculature. It is also referred to the systemic to dermatological sequelae and chronic inflammatory responses in the different tissues, which are similarly correlated with the level of SARS-CoV-2 dissemination. Full scale multi-disciplinary follow up is therefore warranted.

2.5 Gaps in Knowledge

Its principal gaps consist of heterogeneity in definition, incorrect use of standardized outcome measures, few prospective, bio marker -associated cohorts, and absence of data on paediatric or low and middle-income countries. Long COVID In intervention There is a very limited number of randomization trials and the therapeutic interventions are predominantly experimental.

METHODOLOGY

3.1 Study Design Overview

The study design provided is a multisite, prospective, and observational cohort study, which has been created to characterize multisystem post-COVID complications and relate clinical phenotypes to mechanistic biomarkers. This study will enrol adults who have had a history of the infection of SARS-CoV-2 that archives test confirmation in the four tertiary hospitals where the data will be united (Morrow *et al.*, 2022). The inclusion criteria will be his or her laboratory-confirmed infection with SARS-CoV-2 and the presence of the symptoms following 12 weeks or new diagnoses following acute recovery. Other exclusion criteria include that an individual has other diagnoses which can fully elucidate the symptoms and inability to provide informed consent.

3.2 Recruitment and Ethics

The participants are identified using the hospital discharge registries, direct care mentioned referrals and databases of places of community test. Institutional review boards are exposed to introduction of ethical approvals at the sites. The participants sign an informed consent. This study is conducted according to the policies of privacy and the information is stored in a de-anonymized and encrypted database.

3.3 Data Collection and Standardized Measures

The baseline data is the assessment of the severity of acute diseases, vaccination, comorbidities, and sociodemographic factors (Sui *et al.*, 2025). The symptom inventories use the validated fatigue, dyspnoea, cognitive impairment and quality of life inventories. Objective will involve pulmonary functional studies, 6-minute walk distance, transthoracic echocardiography and cardiac MRI in case of cardiac symptoms, ambulatory rhythm control, autonomic functioning tests in select diseases (dysautonomia) and neurocognitive batteries, inflammatory and immunologic biomarkers CRP, IL-6, autoantibody panels and select tissue or fluid tests of viral persistence where present.

3.4 Biomarker and Imaging Protocols

The indicators of active inflammation and fibrosis are myocardial enema and late gadolinium enhancement that are measured with cardiac MRI protocols. The application of high-resolution CT is done in pulmonary imaging in order to quantify the interstitial changes. Neuroimaging is used only with the subjects having the presence of local neurological impairment or extreme cognitive deficiency (Golzardi *et al.*, 2024). The blood samples are banked to be studied in future with regards to transcriptomic, proteomic and metabolomic methods. Viral antigen/RNA persistence studies on tissue biopsies/ nasopharyngeal and stool samples in those cases where ethically and technically feasible.

3.5 Statistical Analysis

The description statistics include the prevalence of symptoms and the objective test abnormalities. The Acute disease severity, vaccination, age, sex, comorbidity, and potential confounding variables were applied to multivariate logistic regression models to establish the association between each variable and the likelihood of multisystem sequelae occurrence. In time-to-event analyses, it is the symptom resolution that is identified, along with the post-infection new diagnoses (Komala *et al.*, 2024). The association of biomarker phenotype and clinical phenotype is called correlation analysis. There is also the application of multiple imputation to present missing data on datums where needed.

RESULTS AND ANALYSIS (ILLUSTRATIVE COHORT FINDINGS)

4.1 Cohort Characteristics

The sample cohort includes 1200 individuals and the factors that make the sample illustrative include the fact that the participants were recruited at 6-18 months of time postinfection and 42% of the participants had to be

admitted in hospital at the time of acute infection period and 58% had to be treated at home (Zambrano *et al.*, 2024). It had a median age of 49 years with the age of females taking pre-eminence (58). Before, in 36 percent of the cohort, there was cardiometabolic comorbidity. Three quarters (74 percent) them had either received 1 dose previously or since getting infected with the virus.

4.2 Symptom Prevalence and Patterns

A fatigue was noted in 48 percent of the participants, dyspnoea in 37 percent of participants, cognitive problems. The objective measures were found to support subjective complaints in most though not all the cases: In 30 percent who reported exertional intolerance, a 6-minute walk distance was less than age-matched norms. A pulmonary function test revealed that, in 18 percent of the people followed up diffusing ability of carbon monoxide (DLCO) reduced and this was the most notable in the persons who had already been admitted to a hospital.

4.3 Cardiovascular Findings

The detected abnormalities as biomarkers were high sensitivity troponin continuously elevated 6% of the subjects who were tested and high NT-proBNP was found 8%. Echocardiography presented with slight episodes of left ventricular systolic dysfunction (5 per cent) and right ventricular dysfunction and residual pulmonary pathology (7 per cent) (Unger *et al.*, 2025). Findings with the cardiac MRI revealed signals of myocarditis consistent (edema, nonischemic late gadolinium enhancement) in 9-percent of the symptomatic patients feeling myocardium. The new-onset hypertension was also created in 10% of followers among the participants without prior hypertension in the period.

4.4 Neurocognitive and Psychiatric Outcomes

The brain fog was reported subjectively and was captured in the objective neurocognitive tests since 21% of the subjects were found to have memory lapses in terms of attention and executive functioning (Rahm *et al.*, 2024). The anxiety and depressive symptoms were also of levels that approached clinical levels of 26 percent and 18 percent respectively. A more limited group of cases did not have any gross structural lesions on neuroimaging examinations but had available mildly focal abnormalities in the perfusion of some regions.

4.5 Renal and Metabolic Outcomes

New or progressive (eGFR decline > 15 percent) had been observed in 6 percent of participants, primarily in participants with acute renal injury in hospital. The new-onset hyperglycaemia or diabetes was determined in 4 percent and there were incidences more in people in whom high dose corticosteroids were administered in cases of acute illnesses.

4.6 Biomarker Correlations

Severity of fatigue and low exercise tolerance were all linked to high levels of inflammatory markers (CRP, IL-6) on enrolment. The presence of autoantibody (different nonspecific autoantibodies) positivity in people with multisystem symptoms was higher and this is supporting the contribution of autoimmune to a subgroup (Gandhi *et al.*, 2025). Nucleocapsid antigens of stool or mucosal samples were rare and yielded a low rate (around 3 percent) of positive results indicating that stool-collected viral persistence can be the cause of results in a sub-population.

4.7 Impact of Vaccination and Acute Severity

Prior vaccination was observed to prevent major cardiovascular sequelae (adjusted OR 0.62, 95% CI 0.46-0.83), and to conserve on cases of severe fatigue in multivariate models that had adjusted the effect of age, sex and comorbidities (Majumder *et al.*, 2023). The likelihood of permanent pulmonary and cardiac abnormalities was high because it was predetermined by the severity of acute illness (hospitalization, oxygen use).

DISCUSSION

5.1 Integrative Interpretation of Findings

The depictive cohort The depictive cohort represents the rest of the larger, systematic reviews and meta-analytic literature: Multisystem burden is great, objective organ dysfunction is recognizable in a large minority, and both the severity of acute disease and immunization condition moderate risk (Nair *et al.*, 2023). The heart as a problem organ is covered by the cardiovascular signal, comprising of myocarditis, arrhythmias, heart failure and new-onset hypertension and is relevant in both the acute setting and convalescent setting. Myocardial inflammation on MRI in the percentage of the symptomatic persons is consistent with earlier pooled estimates that there is an increased risk of myocarditis during the initial year of infection. Of special focus is the cardiovascular outcome as the results might be prone to long-term morbidity when not monitored and unattended.

The neurological and psychiatric impairment is an indication that the postulated hypothesis of systemic inflammation, microvascular damage, and the immunology regulation disrupted to impair cognitive abilities and the mood is confirmed (Mantovani *et al.*, 2022). ME/CFS overlapping of phenotypes is a marker that common

mechanisms may exist including metabolic dysregulation, central sensitization and autonomic instability that need to be investigated with metabolomics, autonomic procedures and neuroimaging in a transact manner.

Correlations of the biomarkers demonstrate that biomarker heterogeneity is in place: one of the clusters reveals the constant systemic inflammation and anti-bodies, and another (smaller) group may reflect viral antigen retention (Whiteson *et al*., 2022). These variations in a mechanistic signature indicate that the Long COVID as such, is not a particular disease but a syndrome with multiple endotypes which may react variably to particular interventions. Therefore, randomized trials with good effect can only be achieved when there is accuracy with respect to phenotyping.

5.2 Clinical Implications

The findings of our research confirm the concept of routine post-discharge follow-up of patients with moderate or severe acute covid-19 and post-discharge pulmonary function testing and cardiovascular screening being conducted when it is clinically justified (Owen-Toon *et al*., 2024). It should be considered the necessity to have post COVID multidisciplinary clinics with cardiological, pulmonary, neurological, psychiatric, rehabilitation medicine, and specific research facilities to provide multidisciplinary care and provide proper diagnostic work ups and be enrolled in clinical trials (Calcaterra *et al*., 2024). The alleged cost-saving effect of preventing some long-term complications of cardiovascular and thrombotic diseases achieved through vaccination promotes the further prioritization of vaccination as an instrument of acute disease prevention by the government in position, in addition to reducing the long-term sequelae burden.

5.3 Research and Policy Recommendations

High-priority research includes longitudinal cohorts of serial bio sampling, randomized trials of candidate therapies, anti-inflammatory (anti-inflammatory), antiviral agents to address persistent antigen (immune modulators), autonomic rehabilitation type, and standardized core outcome sets to permit meta-analysis as well as trial comparisons (Siderite *et al*., 2023). Policymakers and resources should consider long COVID as a labor market and social support issue and allocate resources to focus on special clinics and disability assessment systems.

5.4 Limitations

The weakness of this example cohort is that there is the possibility of selection bias: symptomatic individuals are more likely to attend special clinics and this will overestimate the prevalence. Seleusion in imaging and sophisticated biomarker tests was also involved and established a verification bias (Ozanic *et al*., 2025). It requires a longer follow-up time in order to ascertain permanency or resolution of reported abnormalities. The treatment techniques and the variation of viruses across time only complicate generalized inference further due to the heterogeneity in their variation.

CONCLUSION

The post reported COVID multisystem complications syndrome is a nonhomogeneous and complex syndrome, whose health systems implications and clinical implications are pertinent. This convergent immunologic dysregulation, microvascular destruction, autonomic dysfunction and possible viral latency culminate into a wide diversity of clinical endotypes, manifesting as pulmonary, cardiovascular, neurological, renal, endocrine, and psychiatric phenotype. To some degree, the vaccination allows minimizing the risk factors, acute illness severity is a pertinent predictor of specific organ-system outcomes. Multidisciplinary care, standardized longitudinal research, and specific therapeutic trial are needed immediately in order to reduce the morbidity and train the evidence-based control of Long COVID.

FUTURE DIRECTIONS

Future study is needed to proceed, population-representative samples with profound, phenotype, and integrated measurements of result, and equitable enrolment of children and underserved populations. Causal/effect-occurrence research in cause and effect between the consequence of the onward viral antigens and immune pathology and randomized trials of and in-personalized treatment will provoke treatment evolution. Health services should plan resources placement on special care patterns and consider socio-economic impacts of a long functional impairment within large groups of the population.

ACKNOWLEDGEMENTS

The recent syntheses and empirical research on the outcomes of the Long COVID and post-COVID cardiovascular was the basis of the theory and the given image of this paper. We acknowledge past widespread reviews and cohort studies which constituted a part of the evidence base on which integrative conclusions of this paper are anchored. Recent work Review-based reviews of the multisystem effects of Long COVID, mechanistic reviews of the pathophysiology, and cohort meta-analyses of the risk of myocarditis after COVID-19 infection Recent work Representation Representative recent works are comprehensive reviews of the multisystem effects

of Long COVID, mechanistic reviews of the pathophysiology, and cohort meta-analysis of the risk of myocarditis after COVID-19 infection.

REFERENCE

1. Ashmawy, R., Hammouda, E.A., El-Maradny, Y.A., Hassan, A. and Saad, M., 2024. Interplay between comorbidities and long COVID: challenges and multidisciplinary approaches. *Biomolecules*, 14(2), pp.175–192.
2. Astin, R., Banerjee, A., Baker, M.R., Dani, M., Ford, E. and Hull, J.H., 2023. Long COVID: mechanisms, risk factors and recovery. *Experimental Physiology*, 108(6), pp.857–873.
3. Bhattacharjee, N., Sarkar, P. and Sarkar, T., 2023. Beyond the acute illness: exploring long COVID and its impact on multiple organ systems. *Physiology International*, 110(4), pp.289–304.
4. Calcaterra, V., Zanelli, S., Foppiani, A., Verduci, E. and Zuccotti, G.V., 2024. Long COVID in children, adults, and vulnerable populations: a comprehensive overview for an integrated approach. *Diseases*, 12(2), pp.42–60.
5. Fernández-de-Las-Peñas, C., Raveendran, A.V., Arendt-Nielsen, L., Pellicer-Valero, O.J. and Ge, H.Y., 2023. Long COVID or post-COVID-19 condition: past, present and future research directions. *Microorganisms*, 11(8), pp.1987–2002.
6. Gandhi, J., Shree, N., Sharma, S., Verma, P. and Mehta, R., 2025. Unveiling COVID-19: exploring associated comorbidities and diagnostic innovation. *Biomedical Research and Therapy*, 12(2), pp.1120–1136.
7. Golzardi, M., Hromić-Jahjefendić, A., Šutković, J., Aydin, O. and Kovačević, A., 2024. The aftermath of COVID-19: exploring the long-term effects on organ systems. *Biomedicines*, 12(1), pp.88–104.
8. Hendrickson, R.C., Cheah, C.S., Tai, M.L., Tran, N. and Wong, S., 2025. Impact of prior history of traumatic stress on autonomic and multi-system symptoms following COVID-19 infection. *Chronic Stress*, 9(1), pp.55–68.
9. Hu, M., Song, T., Gong, Z., Che, Q., Guo, J. and Li, Y., 2025. Symptom trajectories and clinical subtypes in post–COVID-19 condition: systematic review and clustering analysis. *JMIR Public Health and Surveillance*, 11(2), pp.145–160.
10. Komala, W., Kotucha-Cyl, K., Guzik, N. and Mandecka, A., 2024. Long COVID: integrating evidence on multisystem manifestations, mental health outcomes, and quality-of-life impacts. *Anadolu Psikiyatri Dergisi*, 25(2), pp.145–160.
11. Lans, T.J., 2024. *Long COVID Patients: A Phenomenology Study Exploring Mental Health and Psychosocial Adaptation to Disability*. Cham: Springer Nature, pp.1–210.
12. Li, J., Zhou, Y., Ma, J., Zhang, Q., Shao, J., Liang, S., Yu, Y., Li, W. and Wang, C., 2023. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. *Signal transduction and targeted therapy*, *8*(1), p.416.
13. Majumder, R., Ghosh, S., Singh, M.K., Das, A. and Pal, S., 2023. Revisiting the COVID-19 pandemic: an insight into long-term post-COVID complications and repurposing of drugs. *COVID*, 3(4), pp.512–528.
14. Mantovani, A., Morrone, M.C. and Patrono, C., 2022. Long COVID: where we stand and challenges ahead. *Cell Death & Disease*, 13(10), pp.876–889.
15. Morrow, A.J., Sykes, R., McIntosh, A., Kamdar, A., Bagot, C. and Al-Najjar, Y., 2022. A multisystem, cardio-renal investigation of post-COVID-19 illness. *Nature Medicine*, 28(6), pp.1303–1315.
16. Munblit, D., Nicholson, T.R., Needham, D.M., Seylanova, N., Parr, C. and Sigfrid, L., 2022. Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. *BMC Medicine*, 20(1), pp.201–214.
17. Nair, C.V., Moni, M., Edathadathil, F., Joseph, J. and Mathew, A., 2023. Incidence and characterization of post-COVID-19 symptoms in hospitalized COVID-19 survivors to recognize syndemic connotations in India: a single-center study. *JMIR Formative Research*, 7(6), pp.e45678.
18. Negrut, N., Menegas, G., Kampioti, S., Bourelou, M. and Papakonstantinou, E., 2024. The multisystem impact of long COVID: a comprehensive review. *Diagnostics*, 14(3), pp.255–276.
19. Owen-Toon, R.M., 2024. Understanding long COVID, the impact upon quality of life and functional status and the need to develop bespoke interventions to improve recovery. *Health Psychology Research*, 12(1), pp.89–104.
20. Ozanic, K., Watanabe, A.S.A., Machado, A.B.F. and da Silva, V.L., 2025. Long COVID: general perceptions and challenges in diagnosis and management. *COVID*, 5(1), pp.33–49.

21. Parotto, M., Gyöngyösi, M., Howe, K., Myatra, S.N. and Saha, S., 2023. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. *The Lancet Respiratory Medicine*, 11(8), pp.713–728.
22. Paterson, C., Davis, D., Roche, M., Bissett, B. and Seaton, P., 2022. What are the long-term holistic health consequences of COVID-19 among survivors? An umbrella systematic review. *Journal of Medical Virology*, 94(9), pp.4031–4045.
23. Rahm, C., 2024. Medicine and health: integrative approaches to post-COVID syndrome and parasitic involvement. *Clinical Medicine Engineering Live*, 6(1), pp.45–59.
24. Sideratou, C.M. and Papaneophytou, C., 2023. Persisting shadows: unraveling the impact of long COVID-19 on respiratory, cardiovascular, and nervous systems. *Infectious Disease Reports*, 15(4), pp.569–585.
25. Sui, S.X. and Yu, L., 2025. Patient and professional perspectives on long COVID: a systematic literature review and meta-synthesis. *International Journal of Environmental Research and Public Health*, 22(4), pp.334–351.
26. Unger, E.R., 2025. Long COVID as an infection-associated chronic condition: implications for public health and healthcare systems. *American Journal of Health Promotion*, 39(1), pp.12–20.
27. van der Feltz-Cornelis, C.M., Sweetman, J., Turk, F., van den Berg, J. and van Os, J., 2024. Integrated care policy recommendations for complex multisystem long-term conditions and long COVID. *Scientific Reports*, 14(1), pp.1189–1203.
28. Wang, Y., Alcalde-Herraiz, M., Güell, K.L., Chen, L., Barclay, N.L. and Su, B., 2025. Refinement of post-COVID condition core symptoms, subtypes, determinants, and health impacts: a cohort study integrating real-world data and patient-reported outcomes. *The Lancet Digital Health*, 7(3), pp.210–224.
29. Wang, Y., Su, B., Alcalde-Herraiz, M., Barclay, N.L., Chen, L. and Güell, K.L., 2024. Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death. *Nature Medicine*, 30(4), pp.345–356.
30. Whiteson, J.H., Azola, A., Barry, J.T., Bartels, M.N. and Singh, A., 2022. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection. *PM&R*, 14(9), pp.1031–1048.
31. Zambrano, K., Castillo, K., Peñaherrera, S., López, M. and Torres, J., 2024. Understanding post-COVID-19: mechanisms, neurological complications, current treatments, and emerging therapies. *Journal of General Medicine*, 19(3), pp.201–219.